Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) has received approval from the National Medical Products Administration for the marketing application of Citric Acid Tianeptine, an anti-anxiety medication used for various anxiety states caused by neuroses, such as generalized anxiety disorder, and anxiety states associated with primary hypertension and peptic ulcers [1]. Group 1 - The company has been granted a marketing approval notice for Citric Acid Tianeptine, with the notification number 2026YS00030 [1]. - Citric Acid Tianeptine is primarily indicated for treating anxiety states resulting from various neuroses [1]. - The medication is also applicable for anxiety states associated with physical conditions such as primary hypertension and peptic ulcers [1].

Core Viewpoint - The approval of the citric acid tianeptine raw material drug by the National Medical Products Administration will enhance the company's product portfolio and competitiveness, although it will not have a significant short-term impact on performance [1] Group 1: Product Approval - The company has received the approval notice for the citric acid tianeptine raw material drug from the National Medical Products Administration [1] - The drug is classified as an anti-anxiety medication [1] Group 2: Research and Development Investment - The company submitted the listing application in July 2024 and has invested approximately 6.23 million yuan in research and development [1] Group 3: Market Potential - The global market sales for the drug are projected to reach 390 million USD in 2024 and 750 million USD by 2031 [1] Group 4: Impact on Company Performance - The approval will enrich the company's product structure and enhance competitiveness, but it is noted that there will be no significant short-term impact on performance [1] - There are uncertainties associated with drug production and sales [1]